Rafael Holdings, Inc. operates in two primary segments: Pharmaceuticals and Real Estate. The Pharmaceuticals segment focuses on developing therapies targeting cancer, with its lead candidate, CPI-613, undergoing clinical trials for metastatic pancreatic cancer and acute myeloid leukemia. The Real Estate segment generates revenue through leasing a commercial office building and an associated public garage. Revenue from Pharmaceuticals contributes approximately 60% of total revenue, while Real Estate accounts for about 40%. Factors supporting the company's endurance include its innovative drug development pipeline, while risks include the inherent uncertainties in clinical trials and the competitive nature of the pharmaceutical industry.
—
Rafael Holdings, Inc. operates in two primary segments: Pharmaceuticals and Real Estate. The Pharmaceuticals segment focuses on developing therapies targeting cancer, with its lead candidate, CPI-613, undergoing clinical trials for metastatic pancreatic cancer and acute myeloid leukemia. The Real Estate segment generates revenue through leasing a commercial office building and an associated public garage. Revenue from Pharmaceuticals contributes approximately 60% of total revenue, while Real Estate accounts for about 40%. Factors supporting the company's endurance include its innovative drug development pipeline, while risks include the inherent uncertainties in clinical trials and the competitive nature of the pharmaceutical industry.
—
Daily adjusted close
Rafael Holdings, Inc. operates in two primary segments: Pharmaceuticals and Real Estate. The Pharmaceuticals segment focuses on developing therapies targeting cancer, with its lead candidate, CPI-613, undergoing clinical trials for metastatic pancreatic cancer and acute myeloid leukemia. The Real Estate segment generates revenue through leasing a commercial office building and an associated public garage. Revenue from Pharmaceuticals contributes approximately 60% of total revenue, while Real Estate accounts for about 40%. Factors supporting the company's endurance include its innovative drug development pipeline, while risks include the inherent uncertainties in clinical trials and the competitive nature of the pharmaceutical industry.